Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 158   

Articles published

MRK 60.90
price chart
Merck & Co., Inc. To Set Strong Foothold In HCV Market; Should Gilead ...
Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) is on track to establish a strong foothold in the fast expanding market of HCV drugs, offering significant threat to the seemingly undisputed leader in the space, Gilead Sciences, Inc. (NASDAQ:GILD ...
Merck files NDA for combo HCV regimen  Seeking Alpha
Merck Submits NDA to FDA for Grazoprevir/Elbasvi  RTT News
Merck & Co., Inc. Extends Reach Into Immunotherapy Drugs Market; Joins ...
Merck & Co., Inc. (NYSE:MRK) announced on Thursday it is entering into a clinical research collaboration with NanoString Technologies Inc (NASDAQ:NSTG), to develop a particular test to help enhance benefits from the company's potential blockbuster drug ...
Amgen, Merck Expand Collaboration to Head, Neck Cancer  Wall Street Journal
New Drugs From Bristol, Merck At Forefront Of Cancer Meeting  Medical Daily
Stocks to Track: SandRidge Energy, Inc. (NYSE:SD), Merck & Co. Inc. (NYSE ...
Shares of Merck & Co. Inc. (NYSE:MRK), inclined 0.40% to $59.70, during its last trading session. Merck & Co., known as MSD outside the United States and Canada, declared that the company has presented a New Drug Application to the U.S.
The Big Business Of Cancer [Bristol-Myers Squibb Co, Merck & Co., Inc., Kite ...
biotech If you are an American, there is a 1 in 3 chance that you will get cancer during your lifetime. If you are a man, the odds are closer to 1 in 2. And almost everyone in America either knows someone who currently has cancer or who has already ...
Wednesday's Stocks Buzz: Merck & Co. Inc. (NYSE:MRK), MBIA Inc. (NYSE:MBI ...
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection ...
Merck & Co., Inc. (NYSE:MRK)'s EVP & Pres-Global Human Health Adam ...
Two days ago, an insider trading deal was made. Adam Schechter, the EVP & Pres-Global Human Health and an insider of Merck & Co., Inc. (NYSE:MRK) 60.89 +1.19 1.99% sold a total of 10,634 shares of Merck & Co. Inc, worth close to $642,768 USD, ...
Deutsche Bank Reaffirms Hold Rating for Merck & Co. (MRK)  Dakota Financial News
Merck & Co. Given Consensus Recommendation of "Hold" by ...  sleekmoney
Merck & Co. Inc. (MRK) Closes 0.69% Down on the Day for May 26
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -0.69% to $58.97, representing a per-share move of $0.41, on volume of 10.8 million shares for Tuesday.
Merck & Co Inc (NYSE:MRK) close to 52-week high, short interest decreasing
Merck & Co Inc (NYSE:MRK) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $60.1, down by -0.6%, with a volume of 8,039,016 shares against an average volume for the last 3 months of 11,301,000.
Analyst Watch: Merck & Company, Inc. (NYSE:MRK)  Markets Daily
Jefferies Group Raises Merck & Co. Price Target to $66.00 (MRK)  Mideast Time
Analytic Report on Merck & Co Inc (NYSE:MRK)
[Business Wire] Merck & Co Inc (NYSE:MRK)(TREND ANALYSIS) known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2015.
Merck & Co. Assigned AA Credit Rating (MRK)  Dakota Financial News
Large Cap Stocks to Keep Your Eyes on- Merck (MRK), Bank of America (BAC ...  Techsonian (press release)
Merck & Co. Inc. (NYSE:MRK) Submits a New Drug Application to U.S. FDA ...
Merck & Co. Inc. (NYSE:MRK) [Trend Analysis] released that it has submitted a New Drug Application to the U.S. FDA for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult ...